Pharma: Other news to note
Friday, January 24, 2014
The FDA prohibited Ranbaxy Laboratories Ltd., from manufacturing and distributing active pharmaceutical ingredients (API) from its facility in Toansa, India, for FDA-regulated drug products, making the Toansa facility subject to certain terms of a consent decree of permanent injunction entered against the pharma in January 2012.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.